- Home
- VRDN vs IDYA Comparison
VRDN vs IDYA Comparison
Compare VRDN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- IDYA
- Stock Information
- Founded
- VRDN 2006
- IDYA 2015
- Country
- VRDN United States
- IDYA United States
- Employees
- VRDN N/A
- IDYA N/A
- Industry
- VRDN Medical Specialities
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- IDYA Health Care
- Exchange
- VRDN Nasdaq
- IDYA Nasdaq
- Market Cap
- VRDN 2.7B
- IDYA 2.9B
- IPO Year
- VRDN N/A
- IDYA 2019
- Fundamental
- Price
- VRDN $30.44
- IDYA $34.21
- Analyst Decision
- VRDN Strong Buy
- IDYA Buy
- Analyst Count
- VRDN 11
- IDYA 14
- Target Price
- VRDN $39.60
- IDYA $49.58
- AVG Volume (30 Days)
- VRDN 1.8M
- IDYA 992.0K
- Earning Date
- VRDN 11-05-2025
- IDYA 11-04-2025
- Dividend Yield
- VRDN N/A
- IDYA N/A
- EPS Growth
- VRDN N/A
- IDYA N/A
- EPS
- VRDN N/A
- IDYA N/A
- Revenue
- VRDN $70,789,000.00
- IDYA $214,834,000.00
- Revenue This Year
- VRDN N/A
- IDYA $90.17
- Revenue Next Year
- VRDN $37,670.06
- IDYA $217.29
- P/E Ratio
- VRDN N/A
- IDYA N/A
- Revenue Growth
- VRDN 23340.07
- IDYA 5377.66
- 52 Week Low
- VRDN $9.90
- IDYA $13.45
- 52 Week High
- VRDN $30.77
- IDYA $34.66
- Technical
- Relative Strength Index (RSI)
- VRDN 77.12
- IDYA 68.23
- Support Level
- VRDN $28.33
- IDYA $31.15
- Resistance Level
- VRDN $29.58
- IDYA $34.66
- Average True Range (ATR)
- VRDN 1.32
- IDYA 1.58
- MACD
- VRDN 0.18
- IDYA 0.11
- Stochastic Oscillator
- VRDN 95.37
- IDYA 89.86
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.